AR Is Required for ER Activity in Breast Cancer

This study suggests that AR plays a previously unrecognized role in supporting E2-mediated ER activity in ER+/AR+ breast cancer cells, and that enzalutamide may be an effective therapeutic in ER+/AR+ breast cancers. Mol Cancer Res; 14(11); 1054–67. ©2016 AACR.

Source: Molecular Cancer Research - November 9, 2016 Category: Cancer & Oncology Authors: D'Amato, N. C., Gordon, M. A., Babbs, B., Spoelstra, N. S., Carson Butterfield, K. T., Torkko, K. C., Phan, V. T., Barton, V. N., Rogers, T. J., Sartorius, C. A., Elias, A., Gertz, J., Jacobsen, B. M., Richer, J. K. Tags: Chromatin, Epigenetics, and RNA Regulation Source Type: research